Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT06313918 Recruiting - Bipolar Disorder Clinical Trials

Exercise Therapy in Mental Disorders-study

Start date: September 27, 2023
Phase: N/A
Study type: Interventional

The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder. The overall aim is to determine which of the two is superior in a long-term perspective.

NCT ID: NCT06304233 Recruiting - Schizophrenia Clinical Trials

The Protein Disrupted in Schizophrenia 1 (DISC1) as a Novel Biomarker for Cardiac Disease

Start date: December 13, 2023
Phase:
Study type: Observational

To study the association between DISC1 RNA expression levels and cardiac function in patients with schizophrenia.

NCT ID: NCT06303596 Not yet recruiting - Schizophrenia Clinical Trials

Hippotherapy in Patients With Schizophrenia

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

This study will determine the efficacy of hippotherapy (horseback-riding) program, as an adjuvant to standard psychiatric treatment, on the outcomes of patients with schizophrenia. A randomized controlled trial is conducted in a Community Mental Health Center. All participants are randomized into two groups (experimental and control groups) using blocked randomization. All participants received the standard psychiatric treatment, while the experimental group is additionally provided with a 16-session hippotherapy program for 8 weeks. All participants will be evaluated using the Positive and Negative Syndrome Scale, State-Trait Anxiety Inventory, Quality of Life Scale, UCLA Loneliness Scale at both baseline and after the intervention.

NCT ID: NCT06301074 Not yet recruiting - Schizophrenia Clinical Trials

The Phase I Study of HS-10509 in Chinese Adult Subjects

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia. Participants will have HS-10509 tablets or placebo once in the single ascending dose (SAD) part or once daily for 28 days in the multiple ascending dose (MAD) part.

NCT ID: NCT06286202 Not yet recruiting - Schizophrenia Clinical Trials

Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial

Start date: May 2024
Phase: N/A
Study type: Interventional

Adults with serious mental illnesses (such as schizophrenia and schizoaffective disorders) often experience a range of cognitive difficulties (such as memory, problem solving difficulties) that affect their ability to lead meaningful life roles. Cognitive remediation is an intervention to address cognitive difficulties in this group of mental health service users. Its implementation in less well-resourced community-based settings is less well-studied. Therefore, the aims of the study are: - To investigate the effects of cognitive remediation on various cognitive skills (such as attention, memory, problem-solving, facial expression recognition, taking others' perspectives etc), for participants with schizophrenia or schizoaffective disorders in community mental health settings. - To investigate if factors such as participants' motivation for engagement and social interaction can affect changes in cognitive skills and functional ability. Participants in the treatment group will attend computer-based cognitive exercises to improve their cognitive skills. They will also participate in group sessions facilitated by therapists to learn how to utilize strategies learned from the computer sessions in their daily lives. Participants in the control group will attend the usual rehabilitation activities in their respective community-based psychiatric rehabilitation centers. This research study will compare the differences in their cognitive performance, functional ability and recovery immediately after the intervention and 8 weeks later.

NCT ID: NCT06284096 Not yet recruiting - Schizophrenia Clinical Trials

The Personal Recovery Based Psychoeducation For Schizophrenia

Start date: June 2024
Phase: N/A
Study type: Interventional

This project aims to introduce a new psychoeducation program that helps individuals with schizophrenia to recover subjectively. The program's effectiveness will be evaluated through a randomized controlled research design. The goal is not only to emphasize clinical recovery but also to highlight the importance of individual recovery and promote its implementation. In this context, the following hypotheses have been formulated. Research Question: 1) Does recovery-based psychoeducation have an impact on the subjective recovery level in individuals diagnosed with schizophrenia in remission? Hypotheses: H0a: Recovery-based psychoeducation does not affect the subjective recovery level in individuals diagnosed with schizophrenia in remission. H0b: Recovery-based psychoeducation does not effect on psychological resilience in individuals diagnosed with schizophrenia in remission. H0c: Recovery-based psychoeducation does not effect on hope in individuals diagnosed with schizophrenia in remission. H1a: Recovery-based psychoeducation affects the subjective recovery level in individuals diagnosed with schizophrenia in remission. H1b: Recovery-based psychoeducation has an effect on psychological resilience in individuals diagnosed with schizophrenia in remission. H1c: Recovery-based psychoeducation has an effect on hope in individuals diagnosed with schizophrenia in remission.

NCT ID: NCT06278532 Recruiting - Schizophrenia Clinical Trials

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Start date: December 11, 2023
Phase:
Study type: Observational

This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.

NCT ID: NCT06278246 Not yet recruiting - Schizophrenia Clinical Trials

Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography

Start date: February 2024
Phase:
Study type: Observational

Within the schizophrenia population, there are individuals that respond to first-line antipsychotic treatments while others do not. The availability of muscarinic M4 subtype receptors (M4R) may play a role as to whether a person with schizophrenia is responsive to first-line antipsychotics or not. The goal of this observational study is to compare the availability of M4R in antipsychotic-free patients with schizophrenia and matched healthy controls. In addition, M4R availability in schizophrenia patients will be examined in relation to response to first line antipsychotics and clinical and cognitive measures. This study may help better understand antipsychotic resistance in schizophrenia and lead to the development of new treatment options, particularly for cognitive deficits and negative symptoms.

NCT ID: NCT06276361 Recruiting - Schizophrenia Clinical Trials

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

QUARTZ
Start date: September 26, 2023
Phase: Phase 1
Study type: Interventional

This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia.

NCT ID: NCT06275451 Not yet recruiting - Schizophrenia Clinical Trials

Qualitative Study of Emotional Regulation in Schizophrenia

QUALI-RES
Start date: February 2024
Phase:
Study type: Observational

The main aim of this study is to investigate emotional regulation in individuals with schizophrenia using a qualitative methodology (semi-structured interview) and, therefore, from the person's point of view. Given the qualitative nature of the methodology used in this study, the investigators have no specific hypothesis. The investigators have a general hypothesis suggesting that the patients' discourse will enable us to highlight the emotional regulation difficulties described in the literature.